Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1359-1362

  Vizirianakis, Ioannis S ^a   Fatouros, Dimitrios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; DOXORUBICIN; DRUG; GOLD NANOPARTICLE; IRON OXIDE; NANOPARTICLE; PACLITAXEL; RECOMBINANT PROTEIN;

BIOCOMPATIBILITY; BIOINFORMATICS; CANCER THERAPY; CLINICAL PRACTICE; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EPIGENETICS; GENOMICS; GENOTYPE; HUMAN; MEDICAL CARE; MEDICAL RESEARCH; METABOLOMICS; NANOMEDICINE; NANOTECHNOLOGY; PATIENT CARE; PATIENT MONITORING; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; TREATMENT RESPONSE;

GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NANOTECHNOLOGY; NEOPLASMS;

EID: 84867664837     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.034     Document Type: Editorial

References (39)

1. Vizirianakis I.S. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine: NBM 2011, 7:11-17.
2. Annual Meeting of the American Physical Society December 29 1959, California Institute of Technology, Caltech.
3. Davis F.F. The origin of PEGnology. Adv. Drug Deliv. Rev. 2002, 54:457-458.
4. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J Contr. Rel. 2012, 160:117-134.
5. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert. Opin. Pharmacother. 2006, 7:1041-1053.
6. Cheng Y., Meyers J.D., Broome A.M., Kenney M.E., Basilion J.P., Burda C. Deep penetration of a PDT drug into tumors by noncovalent drug-gold nanoparticle conjugates. J. Am. Chem. Soc. 2011, 133:2583-2591.
7. Hong S.Y., Tobias G., Al-Jamal K.T., Ballesteros B., Ali-Boucetta H., Lozano-Perez S., Nellist P.D., Sim R.B., Finucane C., Mather S.J., Green M.L., Kostarelos K., Davis B.G. Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging. Nat. Mater. 2010, 9:485-490.
8. Horcajada P., Chalati T., Serre C., Gillet B., Sebrie C., Baati T., Eubank J.F., Heurtaux D., Clayette P., Kreuz C., Chang J.S., Hwang Y.K., Marsaud V., Bories P.N., Cynober L., Gil S., Férey G., Couvreur P., Gref R. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 2010, 9:172-178.
9. Martina M.S., Fortin J.P., Ménager C., Clément O., Barratt G., Grabielle-Madelmont C., Gazeau F., Cabuil V., Lesieur S. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc. 2005, 30:10676-10685.
10. Vizirianakis I.S. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Curr. Drug Deliv. 2004, 1:73-80.
11. Vizirianakis I.S. Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin. Pharmacokinet. 2007, 46:807-824.
12. McNamara L.E., McMurray R.J., Biggs M.J., Kantawong F., Oreffo R.O., Dalby M.J. Nanotopographical control of stem cell differentiation. J. Tissue Eng. 2010, 2010:120623.
13. Cai W., Zhang Y., Kamp T.J. Imaging of induced pluripotent stem cells: from cellular reprogramming to transplantation. Am. J. Nucl. Med. Mol. Imaging 2011, 1:18-28.
14. Notta F., Doulatov S., Laurenti E., Poeppl A., Jurisica I., Dick J.E. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
15. Caruthers S.D., Wickline S.A., Lanza G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 2007, 18:26-30.
16. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
17. Debbage P. Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 2009, 5:153-172.
18. Marchant G.E. Small is beautiful: what can nanotechnology do for personalized medicine?. Curr. Pharmacogenomics Personalized Med. 2009, 7:231-237.
19. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010, 15:171-185.
20. Lasic D.D., Papahadjopoulos D. Liposomes revisited. Science 1995, 267:1275-1276.
21. Bruchez M., Moronne M., Gin P., Weiss S., Alivisatos A.P. Semiconductor nanocrystals as fluorescent biological labels. Science 1998, 281:2013-2016.
22. Jain K.K. Innovative diagnostic technologies and their significance for personalized medicine. Mol. Diagn. Ther. 2010, 14:141-147.
23. Vizirianakis I.S. Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur. J. Pharm. Sci. 2002, 15:243-250.
24. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
25. Tsiftsoglou A.S., Vizirianakis I.S., Strouboulis J. Erythropoiesis: model systems, molecular regulators, and developmental programs. IUBMB Life 2009, 61:800-830.
26. Vizirianakis I.S., Chatzopoulou M., Bonovolias I.D., Nicolaou I., Demopoulos V.J., Tsiftsoglou A.S. Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. J. Med. Chem. 2010, 53:6779-6810.
27. Giarratana M.C., Rouard H., Dumont A., Kiger L., Safeukui I., Le Pennec P.Y., François S., Trugnan G., Peyrard T., Marie T., Jolly S., Hebert N., Mazurier C., Mario N., Harmand L., Lapillonne H., Devaux J.Y., Douay L. Proof of principle for transfusion of in vitro generated red blood cells. Blood 2011, 118:5071-5079.
28. Hiroyama T., Miharada K., Kurita R., Nakamura Y. Plasticity of cells and ex vivo production of red blood cells. Stem Cells Int. 2011, 2011:195780.
29. Godley L.A., Cunningham J., Dolan M.E., Huang R.S., Gurbuxani S., McNerney M.E., Larson R.A., Leong H., Lussier Y., Onel K., Odenike O., Stock W., White K.P., Le Beau M.M. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin. Oncol. 2011, 38:215-224.
30. Patel J.P., Gönen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., Van Vlierberghe P., Dolgalev I., Thomas S., Aminova O., Huberman K., Cheng J., Viale A., Socci N.D., Heguy A., Cherry A., Vance G., Higgins R.R., Ketterling R.P., Gallagher R.E., Litzow M., van den Brink M.R., Lazarus H.M., Rowe J.M., Luger S., Ferrando A., Paietta E., Tallman M.S., Melnick A., Abdel-Wahab O., Levine R.L. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 2012, 366:1079-1089.
31. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J., Canty A.J., Danska J.S., Bohlander S.K., Buske C., Minden M.D., Golub T.R., Jurisica I., Ebert B.L., Dick J.E. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011, 17:1086-1093.
32. Gentles A.J., Plevritis S.K., Majeti R., Alizadeh A.A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010, 304:2706-2715.
33. Gudgin E.J., Huntly B.J. Acute myeloid leukemia: leukemia stem cells write a prognostic signature. Stem Cell Res. Ther. 2011, 2:21.
34. Godley L.A., Le Beau M.M. The histone code and treatments for acute myeloid leukemia. N. Engl. J. Med. 2012, 366:960-961.
35. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 2012, 12:599-612.
36. Chen R., Mias G.I., Li-Pook-Than J., Jiang L., Lam H.Y., Chen R., Miriami E., Karczewski K.J., Hariharan M., Dewey F.E., Cheng Y., Clark M.J., Im H., Habegger L., Balasubramanian S., O'Huallachain M., Dudley J.T., Hillenmeyer S., Haraksingh R., Sharon D., Euskirchen G., Lacroute P., Bettinger K., Boyle A.P., Kasowski M., Grubert F., Seki S., Garcia M., Whirl-Carrillo M., Gallardo M., Blasco M.A., Greenberg P.L., Snyder P., Klein T.E., Altman R.B., Butte A.J., Ashley E.A., Gerstein M., Nadeau K.C., Tang H., Snyder M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307.
37. Stamatoyannopoulos J.A. What does our genome encode?. Genome Res. 2012, 22:1602-1611.
38. Chanock S. Toward mapping the biology of the genome. Genome Res. 2012, 22:1612-1615.
39. Ecker J.R., Bickmore W.A., Barroso I., Pritchard J.K., Gilad Y., Segal E. Genomics: ENCODE explained. Nature 2012, 489:52-55.